Next Article in Journal
Arctiin Inhibits Cervical Cancer Cell Migration and Invasion through Suppression of S100A4 Expression via PI3K/Akt Pathway
Previous Article in Journal
Numerical Investigation on the Anti-Angiogenic Therapy-Induced Normalization in Solid Tumors
Previous Article in Special Issue
PBPK Modeling as a Tool for Predicting and Understanding Intestinal Metabolism of Uridine 5′-Diphospho-glucuronosyltransferase Substrates
Article

Adaptation of the Kirkstall QV600 LLI Microfluidics System for the Study of Gastrointestinal Absorption by Mass Spectrometry Imaging and LC-MS/MS

1
Centre for Mass Spectrometry Imaging, Biomolecular Sciences Research Centre, Sheffield Hallam University, Howard Street, Sheffield S1 1WB, UK
2
CRODA Inc. (B88), New Castle, DE 19720, USA
3
CRODA Europe Ltd., Cowick DN14 9AA, UK
*
Author to whom correspondence should be addressed.
Academic Editor: Jonathan Paul Mochel
Pharmaceutics 2022, 14(2), 364; https://doi.org/10.3390/pharmaceutics14020364
Received: 30 December 2021 / Revised: 26 January 2022 / Accepted: 2 February 2022 / Published: 5 February 2022
Absorption studies on oral drugs can be difficult due to the challenge of replicating the complex structure and environment of the GI tract. Drug absorption studies can be conducted using in vivo and ex vivo animal tissue or animal-free techniques. These studies typically involve the use of Caco-2 cells. However, Caco-2 cells do not incorporate all the cell types found in intestinal tissue and lack P450 metabolizing enzymes. The QV600 LLI system is a microfluidics system designed for use with cell culture. Here, it has been adapted to house appropriate sections of ex vivo porcine tissue to act as a system that models the duodenum section of the small intestine. A pH regulated solution of Atorvastatin was flowed over the apical layer of the GI tissue and a nutrient solution flowed over the basal layer of the tissue to maintain tissue viability. The tissue samples were snap-frozen, cryosectioned, and imaged using MALDI Mass Spectrometry Imaging (MSI). A proof-of-concept study on the effect of excipients on absorption was conducted. Different concentrations of the solubilizing agent were added to the donor circuit of the QV600 LLI. The amount of Atorvastatin in the acceptor circuit was determined to study the effect of the excipient on the amount of drug that had permeated through the tissue. Using these data, Papp, pig values were calculated and compared with the literature. View Full-Text
Keywords: mass spectrometry imaging; microfluidics; Atorvastatin; polysorbate 80 mass spectrometry imaging; microfluidics; Atorvastatin; polysorbate 80
Show Figures

Figure 1

MDPI and ACS Style

Spencer, C.E.; Rumbelow, S.; Mellor, S.; Duckett, C.J.; Clench, M.R. Adaptation of the Kirkstall QV600 LLI Microfluidics System for the Study of Gastrointestinal Absorption by Mass Spectrometry Imaging and LC-MS/MS. Pharmaceutics 2022, 14, 364. https://doi.org/10.3390/pharmaceutics14020364

AMA Style

Spencer CE, Rumbelow S, Mellor S, Duckett CJ, Clench MR. Adaptation of the Kirkstall QV600 LLI Microfluidics System for the Study of Gastrointestinal Absorption by Mass Spectrometry Imaging and LC-MS/MS. Pharmaceutics. 2022; 14(2):364. https://doi.org/10.3390/pharmaceutics14020364

Chicago/Turabian Style

Spencer, Chloe E., Stephen Rumbelow, Steve Mellor, Catherine J. Duckett, and Malcolm R. Clench. 2022. "Adaptation of the Kirkstall QV600 LLI Microfluidics System for the Study of Gastrointestinal Absorption by Mass Spectrometry Imaging and LC-MS/MS" Pharmaceutics 14, no. 2: 364. https://doi.org/10.3390/pharmaceutics14020364

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop